Figure 2.
Tumor lysis syndrome risk stratification, prophylaxis, and monitoring for patients with CLL initiating venetoclax. ALC, absolute lymphocyte count; CrCl, creatinine clearance. Professional illustration by Patrick Lane, ScEYEnce Studios.
Tumor lysis syndrome risk stratification, prophylaxis, and monitoring for patients with CLL initiating venetoclax. ALC, absolute lymphocyte count; CrCl, creatinine clearance. Professional illustration by Patrick Lane, ScEYEnce Studios.
